AIM ImmunoTech Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AIM research report →
Price Chart
About the company
AIM ImmunoTech Inc. , an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts.
- CEO
- Thomas K. Equels
- IPO
- 1995
- Employees
- 19
- HQ
- Ocala, FL, US
Get TickerSpark's AI analysis on AIM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.57M
- P/E
- -0.05
- Fwd P/E
- 1.43
- PEG
- -0.00
- P/S
- 50.27
- P/B
- 0.53
- EV/EBITDA
- 0.17
- Div Yield
- 0.00%
- Gross Margin
- -8.79%
- Op Margin
- -12800.00%
- Net Margin
- -15526.37%
- ROE
- -789.11%
- ROIC
- -159.32%
Latest fiscal year · YoY change
- Revenue
- $88.00K-48.2%
- Gross Profit
- $-250,000-279.9%
- Op Income
- $-10,526,000
- Net Income
- $-13,958,000+19.4%
- EPS
- $-8.62+23.2%
- OCF Growth
- +26.4%
- FCF Growth
- +24.0%
- 52W High
- $1.88
- 52W Low
- $0.11
- 50D MA
- $0.17
- 200D MA
- $0.42
- Beta
- 1.31
- RSI (14)
- 27
- Avg Volume
- 4.39M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
AIM ImmunoTech highlighted clinical progress across several Ampligen programs, but the call was also notable for limited cash and an active effort to protect its NYSE American listing.· April 1, 2025
- DURIPANC in metastatic pancreatic cancer advanced into Phase 2, with final patient enrollment now expected in the second or third quarter of 2026.
- The company said its AMP-518 long-COVID study is complete and it is planning a follow-up study based on the data.
- A new FluMist/Ampligen influenza study is planned, including potential coverage for avian flu, with Dr. Paul Goepfert named as principal investigator.
- Management said cash, cash equivalents and marketable securities were about $4 million at December 31, 2024.
- AIM is preparing a special stockholder meeting to authorize a reverse stock split as part of efforts to avoid delisting from NYSE American.
Management said cash, cash equivalents and marketable securities were approximately $4 million as of December 31, 2024. For the year ended December 31, 2024, research and development expense was $6.2 million versus $10.9 million in 2023, and general and administrative expense was $13.7 million versus $21.1 million in 2023. No revenue, EPS, gross margin, or formal next-quarter/full-year financial guidance was given on the call. Operationally, the company said DURIPANC has entered Phase 2 dosing, the ovarian cancer study is expected to complete in the first half of 2025, first dosing in the melanoma study is expected in the first half of 2025, and the TNBC study is expected to complete enrollment in the second quarter of 2026.
Thomas Equels emphasized that AIM is building momentum across multiple Ampligen programs in oncology, post-COVID conditions, and influenza. He framed recent updates as evidence of broad clinical potential and said the company is moving toward several inflection points, including Phase 2 dosing in pancreatic cancer, a planned follow-up long-COVID study, and a new influenza vaccine collaboration with the University of Alabama-Birmingham. His tone was optimistic, but he also acknowledged the practical need to secure capital and maintain the company’s exchange listing.
No dedicated CFO spoke on the call; Equels covered the financials. He stated cash, cash equivalents and marketable securities were about $4 million at December 31, 2024, and highlighted lower 2024 operating spend versus 2023, with R&D at $6.2 million and G&A at $13.7 million. He also said the company is actively evaluating options to remain compliant with NYSE American requirements, including a potential reverse stock split and a stockholder meeting within about a month to authorize one if needed.
The only analyst question focused on whether AIM has enough Ampligen supply for this year’s trials and how difficult it would be to obtain more. Management said current supply should be sufficient for ongoing studies absent an unforeseen issue, but additional future trials would require manufacturing more Ampligen, which would require capital. Equels said the company is working with polymer manufacturers and other vendors needed for production and does not expect to run out of supply in the near term.
The bull case is that AIM has multiple clinical programs moving forward at once, including Phase 2 dosing in pancreatic cancer and planned data or enrollment milestones in ovarian cancer, melanoma, TNBC, long COVID, and influenza. Management also pointed to external validation through partnerships and grant funding from AstraZeneca, Merck, the National Cancer Institute, and academic centers.
The main risks are financial and listing-related: the company reported only about $4 million in cash, cash equivalents and marketable securities at year-end, and said future Ampligen manufacturing will require capital. Management also said it is working to avoid delisting from NYSE American and may need a reverse stock split, which underscores balance-sheet and market-cap pressure.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 68.9%
- Shares Outstanding
- 39.92M
- Float Shares
- 27.51M
of shares held by institutions
1 13F filers
Buy/sell ratio 5.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Inc. | 698.27K | ▼ 66 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 18, 26 | KELLNER TED D | sell | 14,574 |
| Nov 18, 26 | KELLNER TED D | sell | 250 |
| Nov 19, 26 | Equels Thomas K | buy | 50,000 |
| Nov 18, 26 | Equels Thomas K | buy | 20,000 |
| Nov 16, 26 | Equels Thomas K | buy | 38,000 |
| Nov 11, 26 | Equels Thomas K | buy | 35,000 |
| Nov 10, 26 | Equels Thomas K | buy | 39,000 |
| Nov 9, 26 | Equels Thomas K | buy | 31,298 |
| Nov 6, 26 | Equels Thomas K | buy | 12,751 |
| Nov 6, 26 | Equels Thomas K | buy | 20,299 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AIM coverage
Recent articles, reports, and earnings notes.
No research on AIM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AIM report →AIM ImmunoTech Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting
globenewswire.com · Nov 18
AIM ImmunoTech Approaches Major Clinical Inflection Point with Phase 2 Pancreatic Cancer Data Expected Q1 2027; Reports Third Quarter 2026 Financial Results
globenewswire.com · Nov 13
AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series
globenewswire.com · Nov 10
What Aimia (AIM) Said on Its Q3 Earnings Call
marketbeat.com · Nov 7
AIM ImmunoTech Highlights Ampligen® Opportunity to Potentially Extend Benefits of RAS-Targeted Therapies in Pancreatic Cancer
globenewswire.com · Nov 5
AIM ImmunoTech's Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays
globenewswire.com · Oct 7
AIM ImmunoTech Highlights Recent Media Coverage of Ampligen's® Broad-Spectrum Antiviral and Biodefense Potential
globenewswire.com · Oct 5
AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data
globenewswire.com · Oct 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.